Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 105 Carcinoma, Hepatocellular 34 Neoplasm Metastasis 19 Neoplasms 17 Gastrointestinal Stromal Tumors 17 Colonic Neoplasms 14 Rectal Neoplasms 12 Liver Neoplasms 8 Glioblastoma 7 Sarcoma 6 Stomach Neoplasms 5 Sarcoma, Ewing 5 Ovarian Neoplasms 5 Osteosarcoma 5 Melanoma 5 Cholangiocarcinoma 5 Adenocarcinoma 5 Pancreatic Neoplasms 4 Esophageal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Rhabdomyosarcoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Leukemia, Myeloid, Acute 3 Colorectal Cancer Metastatic 3 Carcinoma, Transitional Cell 3 Carcinoma 3 Advanced Colorectal Cancer 3 Thyroid Neoplasms 2

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

MCRC × regorafenib × Clear all

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡